IL107458A0 - Conjugate vaccine against group b streptococcus - Google Patents

Conjugate vaccine against group b streptococcus

Info

Publication number
IL107458A0
IL107458A0 IL10745893A IL10745893A IL107458A0 IL 107458 A0 IL107458 A0 IL 107458A0 IL 10745893 A IL10745893 A IL 10745893A IL 10745893 A IL10745893 A IL 10745893A IL 107458 A0 IL107458 A0 IL 107458A0
Authority
IL
Israel
Prior art keywords
streptococcus
vaccine against
conjugate vaccine
against group
group
Prior art date
Application number
IL10745893A
Other languages
English (en)
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital filed Critical Gen Hospital Corp
Publication of IL107458A0 publication Critical patent/IL107458A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL10745893A 1992-11-02 1993-11-01 Conjugate vaccine against group b streptococcus IL107458A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02

Publications (1)

Publication Number Publication Date
IL107458A0 true IL107458A0 (en) 1994-02-27

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10745893A IL107458A0 (en) 1992-11-02 1993-11-01 Conjugate vaccine against group b streptococcus

Country Status (14)

Country Link
EP (1) EP0669985A1 (fi)
JP (1) JPH08505282A (fi)
KR (1) KR100349331B1 (fi)
AU (1) AU689452B2 (fi)
CA (1) CA2146926A1 (fi)
FI (1) FI951979A (fi)
HU (1) HU220198B (fi)
IL (1) IL107458A0 (fi)
NO (1) NO951629L (fi)
NZ (1) NZ258684A (fi)
PL (1) PL177302B1 (fi)
RU (1) RU2209247C2 (fi)
WO (1) WO1994010317A2 (fi)
ZA (1) ZA938171B (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
JP2002531054A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド Ｂ群連鎖球菌由来の核酸およびタンパク質
CN1733800A (zh) * 1998-12-22 2006-02-15 微科学有限公司 外表面蛋白质及其基因和用途
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
GB9910375D0 (en) * 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
JP4102186B2 (ja) 2000-10-13 2008-06-18 アイディー バイオメディカル コーポレイション グループｂストレプトコッカスのｂｖｈ−ａ２及びｂｖｈ−ａ３抗原
WO2004080490A2 (en) 2003-03-07 2004-09-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
PT2144924T (pt) 2007-04-16 2016-08-17 Minervax Aps Vacina de proteína de fusão
PT2329020E (pt) 2008-08-28 2013-06-20 Novartis Ag Apresentação na superfície celular de isoformas de polipéptidos através da transleitura de codões de terminação
CN108135992A (zh) 2015-10-21 2018-06-08 米纳瓦克斯有限责任公司 免疫原性融合蛋白
US10888610B2 (en) 2015-12-30 2021-01-12 Minerv Ax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
BR112022008761A2 (pt) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein

Also Published As

Publication number Publication date
AU5665494A (en) 1994-05-24
FI951979A (fi) 1995-06-29
NO951629L (no) 1995-07-03
CA2146926A1 (en) 1994-05-11
EP0669985A1 (en) 1995-09-06
KR100349331B1 (ko) 2003-01-06
HU220198B (hu) 2001-11-28
JPH08505282A (ja) 1996-06-11
RU2209247C2 (ru) 2003-07-27
PL308555A1 (en) 1995-08-21
WO1994010317A2 (en) 1994-05-11
PL177302B1 (pl) 1999-10-29
NZ258684A (en) 1997-04-24
KR950704492A (ko) 1995-11-20
FI951979A0 (fi) 1995-04-26
NO951629D0 (no) 1995-04-28
ZA938171B (en) 1995-03-07
AU689452B2 (en) 1998-04-02
HUT70981A (en) 1995-11-28
WO1994010317A3 (en) 1994-07-07

Similar Documents

Publication Publication Date Title
CZ197595A3 (en) Vaccine preparations
EP0566368A3 (en) Cosmetic conjugate
AP9300541A0 (en) Vaccines
AP9300530A0 (en) Vaccines
IL107458A0 (en) Conjugate vaccine against group b streptococcus
ZA937034B (en) Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
GB9215233D0 (en) Vaccines
AU4970193A (en) IPNV vaccine
GB9214871D0 (en) Vaccines
GB9213559D0 (en) Vaccines
ZA93919B (en) Vaccines
GB9201023D0 (en) Vaccines
AU5626998A (en) Conjugate vaccine against group B Streptococcus
IL115197A0 (en) Vaccine preparations
GB9226768D0 (en) Vaccines
SG48106A1 (en) Pneumococcal polyaccharide conjugate vaccine
ZA933541B (en) Vaccines
GB9108748D0 (en) Conjugate
GB9206786D0 (en) Vaccine
GB9206797D0 (en) Vaccine
GB9206788D0 (en) Vaccine
GB9307028D0 (en) Vaccine
GB9213308D0 (en) Vaccine
GB9206789D0 (en) Vaccine